Court Rules FDA Must Divulge Internal Deliberations on Vanda’s Hetlioz sNDA

A federal court has ruled the FDA must share with Vanda Pharmaceutical its internal deliberation notes on why it denied Vanda’s supplemental new drug application (sNDA) for its sleep-disorder drug Hetlioz (tasimelteon) for jet lag.
Source: Drug Industry Daily